Osaka, Japan & Cambridge, Mass., United States: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the
Osaka, Japan & Cambridge, Mass., United States: − Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia
Osaka, Japan: Revenue Growth of +13.4% at Actual Exchange Rates (AER); +5.0% at Constant Exchange Rate (CER) Driven by
Osaka, Japan & Cambridge, Mass., United States: − Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial −
Osaka, Japan & Cambridge, Mass., United States: − Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in
Osaka, Japan & Cambridge, Mass., United States: More Than 22,000 Takeda Employees Selected the FY2024 New Partners: Population Services
Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.
Copyright© 2025 Creative Bharat Powered By A Buzz Company